Literature DB >> 21543501

Binding interactions between soluble HIV envelope glycoproteins and quaternary-structure-specific monoclonal antibodies PG9 and PG16.

Thaddeus M Davenport1, Della Friend, Katharine Ellingson, Hengyu Xu, Zachary Caldwell, George Sellhorn, Zane Kraft, Roland K Strong, Leonidas Stamatatos.   

Abstract

PG9 and PG16 are antibodies isolated from a subject infected with HIV-1 and display broad anti-HIV neutralizing activities. They recognize overlapping epitopes, which are preferentially expressed on the membrane-anchored trimeric form of the HIV envelope glycoprotein (Env). PG9 and PG16 were reported not to bind to soluble mimetics of Env. The engineering of soluble Env proteins on which the PG9 and PG16 epitopes are optimally exposed will support efforts to elicit broad anti-HIV neutralizing antibodies by immunization. Here, we identified several soluble gp140 Env proteins that are recognized by PG9 and PG16, and we investigated the molecular details of those binding interactions. The IgG versions of PG9 and PG16 recognize the soluble trimeric gp140 form less efficiently than the corresponding monomeric gp140 form. In contrast, the Fab versions of PG9 and PG16 recognized the monomeric and trimeric gp140 forms with identical binding kinetics and with binding affinities similar to the high binding affinity of the anti-V3 antibody 447D to its epitope. Our data also indicate that, depending on the Env backbone, the interactions of PG9 and PG16 with gp140 may be facilitated by the presence of the gp41 ectodomain and are independent of the proper enzymatic cleavage of gp140 into gp120 and gp41. The identification of soluble Env proteins that express the PG9 and PG16 epitopes and the detailed characterization of the molecular interactions between these two antibodies and their ligands provide important and novel information that will assist in improving the engineering of future Env immunogens.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21543501      PMCID: PMC3126577          DOI: 10.1128/JVI.00411-11

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  66 in total

1.  Improved elicitation of neutralizing antibodies against primary human immunodeficiency viruses by soluble stabilized envelope glycoprotein trimers.

Authors:  X Yang; R Wyatt; J Sodroski
Journal:  J Virol       Date:  2001-02       Impact factor: 5.103

2.  Immunization of primates with native, recombinant HIV-SF2 gp120 generates broadly effective neutralizing antibodies directed to conformational epitopes.

Authors:  K S Steimer; N L Haigwood
Journal:  AIDS Res Hum Retroviruses       Date:  1992-08       Impact factor: 2.205

3.  Repertoire of neutralizing human monoclonal antibodies specific for the V3 domain of HIV-1 gp120.

Authors:  M K Gorny; J Y Xu; S Karwowska; A Buchbinder; S Zolla-Pazner
Journal:  J Immunol       Date:  1993-01-15       Impact factor: 5.422

4.  Mutational analysis of the assembly domain of the HIV-1 envelope glycoprotein.

Authors:  P L Earl; B Moss
Journal:  AIDS Res Hum Retroviruses       Date:  1993-07       Impact factor: 2.205

5.  Measuring vaccine-induced HIV neutralization: report of a workshop.

Authors:  C V Hanson
Journal:  AIDS Res Hum Retroviruses       Date:  1994-06       Impact factor: 2.205

6.  Safety and immunogenicity of Env 2-3, a human immunodeficiency virus type 1 candidate vaccine, in combination with a novel adjuvant, MTP-PE/MF59. NIAID AIDS Vaccine Evaluation Group.

Authors:  M C Keefer; B S Graham; M J McElrath; T J Matthews; D M Stablein; L Corey; P F Wright; D Lawrence; P E Fast; K Weinhold; R H Hsieh; D Chernoff; C Dekker; R Dolin
Journal:  AIDS Res Hum Retroviruses       Date:  1996-05-20       Impact factor: 2.205

7.  Neutralization of multiple laboratory and clinical isolates of human immunodeficiency virus type 1 (HIV-1) by antisera raised against gp120 from the MN isolate of HIV-1.

Authors:  P W Berman; T J Matthews; L Riddle; M Champe; M R Hobbs; G R Nakamura; J Mercer; D J Eastman; C Lucas; A J Langlois
Journal:  J Virol       Date:  1992-07       Impact factor: 5.103

8.  Prevalence of cross-reactive HIV-1-neutralizing activity in HIV-1-infected patients with rapid or slow disease progression.

Authors:  Marit J van Gils; Zelda Euler; Becky Schweighardt; Terri Wrin; Hanneke Schuitemaker
Journal:  AIDS       Date:  2009-11-27       Impact factor: 4.177

9.  Immunization with envelope subunit vaccine products elicits neutralizing antibodies against laboratory-adapted but not primary isolates of human immunodeficiency virus type 1. The National Institute of Allergy and Infectious Diseases AIDS Vaccine Evaluation Group.

Authors:  J R Mascola; S W Snyder; O S Weislow; S M Belay; R B Belshe; D H Schwartz; M L Clements; R Dolin; B S Graham; G J Gorse; M C Keefer; M J McElrath; M C Walker; K F Wagner; J G McNeil; F E McCutchan; D S Burke
Journal:  J Infect Dis       Date:  1996-02       Impact factor: 5.226

10.  Broad and potent neutralizing antibodies from an African donor reveal a new HIV-1 vaccine target.

Authors:  Laura M Walker; Sanjay K Phogat; Po-Ying Chan-Hui; Denise Wagner; Pham Phung; Julie L Goss; Terri Wrin; Melissa D Simek; Steven Fling; Jennifer L Mitcham; Jennifer K Lehrman; Frances H Priddy; Ole A Olsen; Steven M Frey; Phillip W Hammond; Stephen Kaminsky; Timothy Zamb; Matthew Moyle; Wayne C Koff; Pascal Poignard; Dennis R Burton
Journal:  Science       Date:  2009-09-03       Impact factor: 47.728

View more
  34 in total

1.  HIV-1 envelope trimer elicits more potent neutralizing antibody responses than monomeric gp120.

Authors:  James M Kovacs; Joseph P Nkolola; Hanqin Peng; Ann Cheung; James Perry; Caroline A Miller; Michael S Seaman; Dan H Barouch; Bing Chen
Journal:  Proc Natl Acad Sci U S A       Date:  2012-07-05       Impact factor: 11.205

2.  Analysis of a clonal lineage of HIV-1 envelope V2/V3 conformational epitope-specific broadly neutralizing antibodies and their inferred unmutated common ancestors.

Authors:  Mattia Bonsignori; Kwan-Ki Hwang; Xi Chen; Chun-Yen Tsao; Lynn Morris; Elin Gray; Dawn J Marshall; John A Crump; Saidi H Kapiga; Noel E Sam; Faruk Sinangil; Marie Pancera; Yang Yongping; Baoshan Zhang; Jiang Zhu; Peter D Kwong; Sijy O'Dell; John R Mascola; Lan Wu; Gary J Nabel; Sanjay Phogat; Michael S Seaman; John F Whitesides; M Anthony Moody; Garnett Kelsoe; Xinzhen Yang; Joseph Sodroski; George M Shaw; David C Montefiori; Thomas B Kepler; Georgia D Tomaras; S Munir Alam; Hua-Xin Liao; Barton F Haynes
Journal:  J Virol       Date:  2011-07-27       Impact factor: 5.103

3.  Characterization of structural features and diversity of variable-region determinants of related quaternary epitopes recognized by human and rhesus macaque monoclonal antibodies possessing unusually potent neutralizing activities.

Authors:  Chavdar Krachmarov; Zhong Lai; William J Honnen; Aidy Salomon; Miroslaw K Gorny; Susan Zolla-Pazner; James Robinson; Abraham Pinter
Journal:  J Virol       Date:  2011-08-10       Impact factor: 5.103

4.  A multivalent clade C HIV-1 Env trimer cocktail elicits a higher magnitude of neutralizing antibodies than any individual component.

Authors:  Christine A Bricault; James M Kovacs; Joseph P Nkolola; Karina Yusim; Elena E Giorgi; Jennifer L Shields; James Perry; Christy L Lavine; Ann Cheung; Katharine Ellingson-Strouss; Cecelia Rademeyer; Glenda E Gray; Carolyn Williamson; Leonidas Stamatatos; Michael S Seaman; Bette T Korber; Bing Chen; Dan H Barouch
Journal:  J Virol       Date:  2014-12-24       Impact factor: 5.103

5.  Antigenicity and immunogenicity of RV144 vaccine AIDSVAX clade E envelope immunogen is enhanced by a gp120 N-terminal deletion.

Authors:  S Munir Alam; Hua-Xin Liao; Georgia D Tomaras; Mattia Bonsignori; Chun-Yen Tsao; Kwan-Ki Hwang; Haiyan Chen; Krissey E Lloyd; Cindy Bowman; Laura Sutherland; Thomas L Jeffries; Daniel M Kozink; Shelley Stewart; Kara Anasti; Frederick H Jaeger; Robert Parks; Nicole L Yates; R Glenn Overman; Faruk Sinangil; Phillip W Berman; Punnee Pitisuttithum; Jaranit Kaewkungwal; Sorachai Nitayaphan; Nicos Karasavva; Supachai Rerks-Ngarm; Jerome H Kim; Nelson L Michael; Susan Zolla-Pazner; Sampa Santra; Norman L Letvin; Stephen C Harrison; Barton F Haynes
Journal:  J Virol       Date:  2012-11-21       Impact factor: 5.103

6.  Diverse recombinant HIV-1 Envs fail to activate B cells expressing the germline B cell receptors of the broadly neutralizing anti-HIV-1 antibodies PG9 and 447-52D.

Authors:  Andrew T McGuire; Jolene A Glenn; Adriana Lippy; Leonidas Stamatatos
Journal:  J Virol       Date:  2013-12-18       Impact factor: 5.103

7.  Functional Stability of HIV-1 Envelope Trimer Affects Accessibility to Broadly Neutralizing Antibodies at Its Apex.

Authors:  Syna Kuriakose Gift; Daniel P Leaman; Lei Zhang; Arthur S Kim; Michael B Zwick
Journal:  J Virol       Date:  2017-11-30       Impact factor: 5.103

Review 8.  Role of human immunodeficiency virus type 1 envelope structure in the induction of broadly neutralizing antibodies.

Authors:  F Benjelloun; P Lawrence; B Verrier; C Genin; S Paul
Journal:  J Virol       Date:  2012-09-26       Impact factor: 5.103

Review 9.  Modern Techniques for the Isolation of Extracellular Vesicles and Viruses.

Authors:  Ryan P McNamara; Dirk P Dittmer
Journal:  J Neuroimmune Pharmacol       Date:  2019-09-12       Impact factor: 4.147

10.  Asymmetric recognition of the HIV-1 trimer by broadly neutralizing antibody PG9.

Authors:  Jean-Philippe Julien; Jeong Hyun Lee; Albert Cupo; Charles D Murin; Ronald Derking; Simon Hoffenberg; Michael J Caulfield; C Richter King; Andre J Marozsan; Per Johan Klasse; Rogier W Sanders; John P Moore; Ian A Wilson; Andrew B Ward
Journal:  Proc Natl Acad Sci U S A       Date:  2013-02-20       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.